<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10604742</article-id><article-id pub-id-type="pmc">2362960</article-id><article-id pub-id-type="pii">6690343</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6690343</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/<italic>neu</italic>-overexpressing metastatic breast cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tokuda</surname><given-names>Y</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Watanabe</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Omuro</surname><given-names>Y</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ando</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Katsumata</surname><given-names>N</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Okumura</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ohta</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Fujii</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Sasaki</surname><given-names>Y</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Niwa</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Surgery, Tokai University School of Medicine, Bohseidai, Isehara, Kanagawa 259-1193, Japan</aff><aff id="aff2"><label>2</label>National Cancer Center Hospital, Tokyo 104-0045, Japan</aff><aff id="aff3"><label>3</label>National Cancer Center Hospital East, Kashiwa, Chiba 277-0882, Japan</aff><aff id="aff4"><label>4</label>Mitsubishi Chemical Corporation, Yokohama Research Center, Kanagawa 227&#x02013;8502, Japan</aff><pub-date pub-type="ppub"><month>12</month><year>1999</year></pub-date><volume>81</volume><issue>8</issue><fpage>1419</fpage><lpage>1425</lpage><history><date date-type="received"><day>20</day><month>11</month><year>1998</year></date><date date-type="rev-recd"><day>14</day><month>05</month><year>1999</year></date><date date-type="accepted"><day>07</day><month>06</month><year>1999</year></date></history><copyright-statement>Copyright 1999, Cancer Research Campaign</copyright-statement><copyright-year>1999</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>We conducted a phase I pharmacokinetic dose escalation study of a recombinant humanized anti-p185<sup>HER2</sup> monoclonal antibody (MKC-454) in 18 patients with metastatic breast cancer refractory to chemotherapy. Three or six patients at each dose level received 1, 2, 4 and 8 mg kg<sup>&#x02013;1</sup> of MKC-454 as 90-min intravenous infusions. The first dose was followed in 3 weeks by nine weekly doses. Target trough serum concentration has been set at 10 &#x003bc;g ml<sup>&#x02013;1</sup> based on in vitro observations. The mean value of minimum trough serum concentrations at each dose level were 3.58 &#x000b1; 0.63, 6.53 &#x000b1; 5.26, 40.2 &#x000b1; 7.12 and 87.9 &#x000b1; 23.5 &#x003bc;g ml<sup>&#x02013;1</sup> respectively. At 2 mg kg<sup>&#x02013;1</sup>, although minimum trough serum concentrations were lower than the target trough concentration with a wide range of variation, trough concentrations increased and exceeded the target concentration, as administrations were repeated weekly. Finally 2 mg kg<sup>&#x02013;1</sup> was considered to be sufficient to achieve the target trough concentration by the weekly dosing regimen. One patient receiving 1 mg kg<sup>&#x02013;1</sup> had grade 3 fever, one at the 1 mg kg<sup>&#x02013;1</sup> level had severe fatigue defined as grade 3, and one at 8 mg kg<sup>&#x02013;1</sup> had severe bone pain of grade 3. No antibodies against MKC-454 were detected in any patients. Objective tumour responses were observed in two patients; one receiving 4 mg kg<sup>&#x02013;1</sup> had a partial response in lung metastases and the other receiving 8 mg kg<sup>&#x02013;1</sup> had a complete response in soft tissue metastases. These results indicate that MKC-454 is well tolerated and effective in patients with refractory metastatic breast cancers overexpressing the HER2 proto-oncogene. Further evaluation of this agent with 2&#x02013;4 mg kg<sup>&#x02013;1</sup> weekly intravenous infusion is warranted. &#x000a9; 1999 Cancer Research Campaign</p></abstract><kwd-group><kwd>HER2/<italic>neu</italic></kwd><kwd>humanized monoclonal antibody</kwd><kwd>pharmacokinetics</kwd><kwd>phase I study</kwd></kwd-group></article-meta></front></article>


